Compare SU & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SU | INSM |
|---|---|---|
| Founded | 1917 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | SU | INSM |
|---|---|---|
| Price | $44.28 | $191.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | $65.00 | ★ $178.71 |
| AVG Volume (30 Days) | ★ 4.3M | 2.7M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $35,463,676,235.00 | $447,022,000.00 |
| Revenue This Year | $0.64 | $43.10 |
| Revenue Next Year | N/A | $128.25 |
| P/E Ratio | $14.42 | ★ N/A |
| Revenue Growth | N/A | ★ 30.34 |
| 52 Week Low | $30.79 | $60.40 |
| 52 Week High | $45.60 | $212.75 |
| Indicator | SU | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 44.31 |
| Support Level | $43.74 | $202.68 |
| Resistance Level | $45.48 | $206.69 |
| Average True Range (ATR) | 0.80 | 6.67 |
| MACD | -0.21 | -3.09 |
| Stochastic Oscillator | 30.60 | 0.91 |
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil production, petroleum refining in Canada and the U.S., and the company's Petro-Canada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, and renewable fuels. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power. The company's operating segments include Oil Sands, Exploration & Production, Refining & Marketing (R&M), and Corporate & eliminations. Geographically, the company generates a majority of its revenue from Canada.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.